Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.biomerieux-usa.com
Global Number of Employees (Latest): 5,823
Year Founded: 1963
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
bioMérieux, Inc. develops in-vitro diagnostics and microbiology testing services for the treatment of infectious diseases. It offers clinical diagnostics and industrial microbiology products; and researches and develops solutions to treat diseases in the areas of sepsis, healthcare associated infections, HIV, tuberculosis, cancer, cardiovascular diseases, biomarkers, biopharmaceutical control, and food safety. The company also provides healthcare solutions, such as clinical and sepsis solutions; industrial solutions, including food, bio pharma, cosmetics and personal care, blood banks, and veterinary solutions; and total service solutions in the areas of laboratory workflow efficiency. In addition, it offers services in the areas of application support, engineering, service plans, service agreements, environmental monitoring and compliance, workflow optimization, and information management; and training and education services in the areas of healthcare, food safety, bio pharma, and veterinary. bioMérieux, Inc. was founded in 1963 and is based in Durham, North Carolina with additional offices in Hazelwood, Missouri; Lombard, Illinois; Cambridge, Massachusetts; and Saint-Laurent, Canada. bioMérieux, Inc. operates as a subsidiary of bioMérieux S.A.


Financial Information (Currency: CAD, in mm)
Total Revenue
 647.0
Operating Income
-
Total Assets
 488.7
Gross Profit
 323.3
EBITDA
-
Total Debt
-
Net Income
 80.2
Global Number of Employees (Latest)
 5,823
Net Debt
-
U.S. Number of Employees 2021
 5,823
U.S. Number of Employees 2020
 5,020
U.S. Last Year Employee Growth %
 16.0
Private Co. Financial Data  as of Dec-31-2005. * Hover over data point numbers for date and source.

Key Professionals
Name
Title
Merieux, Alexandre 
Chairman & CEO
Giraut, Claire 
Chief Financial Officer and Corporate Vice President
Baguenault, Michel 
Corporate Vice President of Human Resources & Communications and General Secretary
Armstrong, Brian 
Senior Vice President of Clinical Operations- North America
Miller, Mark 
Corporate VP & Chief Medical Officer
Pluquet, Alain 
Corporate VP & Chief Data Officer
Ririe, Kirk 
Corporate VP & Chief Innovation Officer
Steward, Herbert R.
Executive Vice President of North America and General Manager of North America
Whelan, James P.
Executive Vice President of Commercial Services
Thiney, Pierre-Louis
Executive Director of Industry Sales & Marketing

Key Board Members
Name
Title
Merieux, Alexandre 
Chairman & CEO
Ange, Michel 
Outside Director
Merieux, Alain
Director
Archinard, Philippe 
Director
Habert, Benoit 
Outside Director
Hibon, Georges 
Director
Palladino, Michele 
Outside Director


Primary Industry Classification
Biotechnology


Primary Office Location
100 Rodolphe Street | Durham, NC | 27712 | United States
Phone: 800 682 2666   Fax: 800 968 9494

Parent Company
bioMérieux S.A. (ENXTPA:BIM)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Bacterial BarCodes, Inc.
Bacterial BarCodes, Inc. develops and markets DiversiLab, a system offering solutions to track hospital-acquired infections and for environmental control and product safety. It also provides DiversiLab System that provides a semi-automated platform to perform the laboratory work; DiversiLab Software that provides various tools for comparison of isolates; and automated equipment for amplicon detection; reagents, including genus-specific and general fingerprinting kits, chip and reagents, microbial DNA isolation kit, and gel standards. The company was incorporated in 1999 and is based in Athens, Georgia. It has an additional office in Houston, Texas. Bacterial BarCodes, Inc. operates as a subsidiary of bioMérieux, Inc.

United States and Canada
Health Care Technology
-
-
-
Banyan Biomarkers, Inc.
Banyan Biomarkers, Inc. develops biomarkers for the diagnosis, management, and treatment of traumatic brain injuries (TBIs). Its products under pipeline include biomarkers for stroke, depression, hypoxic ischemic encephalopathy (HIE), neuro ICU monitoring, and subacute/chronic TBI. The company also provides a point-of-care diagnostic blood test to detect the presence of mild and moderate brain trauma of head injured patients. Banyan Biomarkers, Inc. was formerly known as Daimonion Diagnostics, LLC and changed its name to Banyan Biomarkers, Inc. in July 2004. The company was founded in 2002 and is headquartered in San Diego, California with an additional office in Alachua, Florida.

United States and Canada
Biotechnology
5.00
-
-
BioFire Diagnostics, LLC
BioFire Diagnostics, LLC provides clinical molecular diagnostic solutions for clinics and laboratories. It offers FilmArray, a multiplex PCR system that sets the standard for syndromic infectious disease molecular diagnostics; FilmArray Torch, a random access system that is designed to meet laboratory’s syndromic infectious disease testing needs; and FilmArray Pneumonia Panel, which aid in the diagnosis of specific agents that cause infections of the lower respiratory tract. BioFire Diagnostics, LLC was formerly known as Idaho Technology, Inc. and changed its name to BioFire Diagnostics, LLC in September 2012. The company was founded in 1990 and is based in Salt Lake City, Utah. BioFire Diagnostics, LLC operates as a subsidiary of bioMérieux, Inc.

United States and Canada
Health Care Equipment
460.00
-
-
Biomerieux Australia Pty. Ltd.

Asia / Pacific
Health Care Equipment
37.00
-
-
bioMérieux Mexico S.A. de C.V.
bioMérieux Mexico S.A. de C.V. engages in design, development, manufacture, and marketing of diagnosis systems. The company is based in México, Mexico. bioMérieux Mexico S.A. de C.V. operates as a subsidiary of bioMérieux, Inc.

Latin America and Caribbean
Health Care Equipment
42.00
-
-
Cambridge Biotech Corporation
Cambridge Biotech Corporation was acquired by bioMerieux Vitek, Inc in 23/10/2004. Cambridge Biotech develops, manufactures, and markets diagnostic kits for use in the diagnosis of diseases caused by retroviruses. Cambridge Biotech was founded in 1990 as a result of a merger between Cambridge Bioscience Corp. and Biotech Research Laboratories Inc. The company is based in Worcester, Massachusetts.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-19-2017
Dec-31-2017
Merger/Acquisition
Buyer
Banyan Biomarkers, Inc.
bioMérieux, Inc.

7.00
Sep-18-2006
Sep-18-2006
Merger/Acquisition
Buyer
Bacterial BarCodes, Inc.
bioMérieux, Inc.
Spectral Genomics, Inc.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-04-2023
Company Conference Presentations
bioMérieux, Inc. Presents at 2023 PDA Pharmaceutical Microbiology Conference, Oct-04-2023 08:45 AM
May-08-2023
Company Conference Presentations
bioMérieux, Inc. Presents at 25th annual Food Safety Summit, May-08-2023
Oct-10-2022
Company Conference Presentations
bioMérieux, Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-10-2022 through Oct-12-2022
Sep-08-2021
Product-Related Announcements
bioMérieux, Inc. GENE-UP NUTRAPLEX PRO Assay Receives First-Ever AOAC Approval for Multiplex USP Pathogen Detection and PCR-Based Culture Confirmation in Nutraceutical Products
Aug-09-2021
Client Announcements
SAS Institute Inc. and bioMérieux, Inc. Join Forces to Fight Antimicrobial Resistance

Competitors
Abbott Laboratories (NYSE:ABT), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), AdvanDx, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc. (NYSE:BIO), Bruker Corporation (NasdaqGS:BRKR), Cepheid, Inc., Danaher Corporation (NYSE:DHR), DiaSorin S.p.A. (BIT:DIA), Eastern Polymer Group Public Company Limited (SET:EPG), F. Hoffmann-La Roche Ltd, GenMark Diagnostics, Inc., Immucor, Inc., Implanet S.A. (ENXTPA:ALIMP), Inova Diagnostics, Inc., Luminex Corporation, Medical Analysis Systems, Inc., Meridian Bioscience, Inc., Ortho-Clinical Diagnostics, Inc., Revvity, Inc. (NYSE:RVTY), Roche Holding AG (SWX:ROG), Shire Pharma Canada ULC (Acquired), Siemens Aktiengesellschaft (XTRA:SIE), Siemens Medical Solutions Diagnostics, Inc., T2 Biosystems, Inc. (NasdaqCM:TTOO), Thermo Fisher Scientific Inc. (NYSE:TMO), Tosoh Bioscience, Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 02:36 AM
bioMérieux, Inc.
bioMerieux Inc
Reports
43
GlobalData

Dec 14, 2022 07:28 PM
bioMérieux, Inc.
bioMerieux Inc
Reports
42
GlobalData

Sep 15, 2022 04:04 AM
bioMérieux, Inc.
bioMerieux Inc
Reports
42
GlobalData

Jun 14, 2022 12:53 AM
bioMérieux, Inc.
bioMerieux Inc
Reports
42
GlobalData

Mar 14, 2022 01:36 AM
bioMérieux, Inc.
bioMerieux Inc
Reports
41
GlobalData

Dec 16, 2021 01:40 AM
bioMérieux, Inc.
bioMerieux Inc
Reports
30
GlobalData

Oct 25, 2021 04:23 AM
bioMérieux, Inc.
bioMerieux Inc - Medical Equipment - Deals and Alliances Profile
Reports
17
GlobalData

Sep 14, 2021 06:24 AM
bioMérieux, Inc.
bioMerieux Inc
Reports
18
GlobalData

Jul 23, 2021 09:46 AM
bioMérieux, Inc.
bioMerieux Inc - Medical Equipment - Deals and Alliances Profile
Reports
17
GlobalData

Jun 22, 2021 11:41 PM
bioMérieux, Inc.
bioMerieux Inc - Medical Equipment - Deals and Alliances Profile
Reports
17


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Apr-01-2011
Dec-31-2010
bioMérieux, Inc.
Company Website
Annual Report
3 MB

Key Board Members Details
Name
Title
Phone
Fax
Email
Merieux, Alexandre 
Chairman & CEO
800 682 2666
800 968 9494

Ange, Michel 
Outside Director
800 682 2666
800 968 9494

Merieux, Alain
Director
800 682 2666
800 968 9494
-
Archinard, Philippe 
Director
800 682 2666
800 968 9494

Habert, Benoit 
Outside Director
800 682 2666
800 968 9494

Hibon, Georges 
Director
800 682 2666
800 968 9494
-
Palladino, Michele 
Outside Director
800 682 2666
800 968 9494

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Merieux, Alexandre 
Chairman & CEO
800 682 2666
800 968 9494

Giraut, Claire 
Chief Financial Officer and Corporate Vice President
800 682 2666
800 968 9494

Baguenault, Michel 
Corporate Vice President of Human Resources & Communications and General Secretary
800 682 2666
800 968 9494

Armstrong, Brian 
Senior Vice President of Clinical Operations- North America
800 682 2666
800 968 9494

Miller, Mark 
Corporate VP & Chief Medical Officer
800 682 2666
800 968 9494

Pluquet, Alain 
Corporate VP & Chief Data Officer
800 682 2666
800 968 9494
-
Ririe, Kirk 
Corporate VP & Chief Innovation Officer
800 682 2666
800 968 9494

Steward, Herbert R.
Executive Vice President of North America and General Manager of North America
800 682 2666
800 968 9494
-
Whelan, James P.
Executive Vice President of Commercial Services
800 682 2666
800 968 9494

Thiney, Pierre-Louis
Executive Director of Industry Sales & Marketing
800 682 2666
800 968 9494
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
